MSDS

INHALATION: Vapor overexposure, and/or inhalation of silica or calcium oxide dust may severely
irritate eyes, nose, throat, upper respiratory tract, and lungs. Vapor overexposure
may cause drowsiness. Excessive inhalation of calcium carbonate (dust form)
may result in shortness of breath or reduced pulmonary function. Inhalation of
high concentrations of BBP, xylene, or ethyl benzene may cause respiratory
irritation or difficulties and central nervous system effects characterized by
headache, nausea, dizziness, and/or drowsiness. MDI vapors or mist can cause
irritation of upper respiratory tract: signs/symptoms can include soreness of the
nose and throat, coughing, and sneezing. Persons previously sensitized to
isocyanates may experience an allergic respiratory reaction: signs/symptoms can
include difficulty breathing, wheezing, tightness of chest, and respiratory failure.
Overexposure to titanium dioxide (dust form) may cause pulmonary fibrosis
(scarring of the lungs).
ORAL: Small amounts transferred to the mouth by fingers during use, etc. should not
injure. Swallowing large amounts may cause digestive discomfort and gastrointestinal irritation.
Ingestion of BBP may cause central nervous system depression with symptoms seen in acute
inhalation. Ingestion of xylene may cause central nervous system effects. Aspiration of xylene or ethyl
benzene into lungs may cause chemical pneumonitis.
SECTION III - HAZARDOUS INGREDIENTS/IDENTITY INFORMATION
This product consists of a mixture/preparation.
CAS
NO.
INGREDIENT WT
%
LETHAL DOSES EXPOSURE LIMITS
TWA STEL Ceiling
ppm mg/m
3
ppm mg/m
3
ppm mg/m
3
Inhalation TCLo –
789 mg/m
3
/6hr (rat)
OSHA
Oral LD50 –
2,330 mg/kg (rat)
NIOSH
ACGIH
85-68-7 Butyl Benzyl Phthalate
(BBP)
15-40
Dermal LD50 –
6,700 mg/kg (rat)
CANADA
No exposure limit guidelines have been established
for this material.
OSHA
- 15, 5
b
- - - -
NIOSH - 10, 5
b
- - - -
ACGIH - 10 - - - -
1317-65-
3
Calcium Carbonate
a
(Limestone)
3-7
Oral LD50 –
7,340 mg/kg (rat)
CANADA - 10, 5
b
- - - -
OSHA - 5 - - - -
NIOSH - 2
c
- - - -
ACGIH - 2 - - - -
1305-78-
8
Calcium Oxide
a
1-5 Not established
CANADA - 2 - 4 - -
Inhalation TCLo –
250 mg/m
3
/6hr (rat)
OSHA - 15
d
- - - -
Oral LD50 –
>24,000 mg/kg (rat)
NIOSH e - - - - -
ACGIH - 10 - - - -
13463-
67-7
Titanium dioxide
a
1-5
Dermal LD50 –
>10,000 mg/m
3
(rabbit)
CANADA - 10, 5
b
- - - -